Form 4: Rocket Pharmaceuticals' General Counsel, Martin Wilson, Sells Shares to Cover Tax Obligations

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 587 shares of common stock on May 20, 2025, at a price of $6.446 per share to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On May 20, 2025, Martin Wilson, the General Counsel of Rocket Pharmaceuticals, sold 587 shares of the company's common stock.
• The sale was executed at a price of $6.446 per share.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Wilson directly owns 149,163 shares of Rocket Pharmaceuticals' common stock.
• The holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a transaction related to tax obligations, which is a routine event. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Comparison to Industry Standards

• Similar transactions are routinely disclosed by executives at comparable biotech companies such as Bluebird Bio, CRISPR Therapeutics, and Beam Therapeutics.
• These companies also use equity compensation extensively, leading to regular Form 4 filings related to vesting and tax obligation sales.

Key Dates

Keywords

Rocket Pharmaceuticals, Martin Wilson, Form 4, Share Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership, RCKT, General Counsel